

Kidney Cancer GCOM 6 minutes

Kidney Cancer update – committee meeting 6 minutes

Date: 18/09/2024

Location: Virtual

Minutes: Final

| Committee members present: | | |
|-----------------------------------|-------------------------------|----------------------------------|
| Baljit Singh | Committee Chair | Present for items 1 – 9 |
| Axel Bex | Urological Surgeon | Present for items 2 – 9 |
| Janet Brown | Medical Oncologist | Present for items 1 – 7 |
| Lisa Browning | Histopathologist | Present for items 1 – 9 |
| Amarnath Challapalli | Clinical Oncologist (General) | Present for items 3 – 7 |
| Amy Clifford | Clinical Oncologist (SABR) | Present for items 1 – 9 |
| John Connolly | Lay Member | Present for items 1 – 9 |
| David Cullen | Urology Cancer Nurse | Present for items 1 – 9 |
| Fayiza Habeeb | Lead Nurse Practitioner | Present for items 1 – 9 |
| Geraldine Fox | Lay Member | Present for items 1 – 9 |
| Ankit Rao | Medical Oncologist | Present for items 1 – 9 |
| Sandeep Singh Randhawa | General Practitioner | Present for items 1 – 9 |
| Grant Stewart | Topic Adviser | Present for items 2 – 5, 7 -9 |
| Maxine Tran | Urological Surgeon | Present for items 1 – 9 |
| Sam Withey | Diagnostic Radiologist | Present for items 1 – 9 |

| In attendance NICE: | | |
|----------------------------|--|-------------------------|
| Adefisayo Abba-Abba | Technical Analyst (observing) | Present for items 1 – 4 |
| Sarah Boyce | Senior Technical Analyst | Present for items 1 – 9 |
| Melanie Carr | Technical Analyst, Professional Team (observing) | Present for items 1 – 2 |
| Lindsay Claxton | Health Economics Adviser | Present for items 1 – 9 |
| Danielle Conroy | Project Manager | Present for items 1 – 9 |
| Olivia Crane | Senior Technical Analyst | Present for items 1 – 2 |
| Amy Finnegan | Senior Information Specialist | Present for items 6 – 7 |
| James Hall | Senior Medical Editor | Present for items 1 – 9 |
| Marie Harrisingh | Topic Lead | Present for items 1 – 9 |
| Lina Manounah | Technical Analyst (observing) | Present for items 3 – 7 |

| | | |
|---------------------|---|-------------------------|
| Katherine Saxby | Medicines Adviser, Medicines Optimisation | Present for items 6 – 9 |
| Maria Smyth | Senior Technical Analyst (observing) | Present for items 1 – 8 |
| Hannah Tebbs | Senior Health Economist | Present for items 1 – 9 |
| Fernando Zanghelini | Technical Analyst | Present for items 1 – 9 |
| Yuanyuan Zhang | Health Economist | Present for items 1 – 9 |

Apologies:

| | |
|------------------|---------------------------------------|
| Victoria Carter | Implementation Support Officer, NICE |
| Stuart Evans | Oncology Pharmacist |
| Benjamin Gregory | Resource Impact |
| Kate Kelley | Associate Director |
| Tze Min Wah | Interventional Radiologist |
| David Mole | Nephrologist (Co-opted member) |
| Vishal Patil | Anaesthetist (Co-opted member) |
| Ana Semedo | Oncology Cancer Nurse (Vice Chair) |
| James Whitworth | Clinical Geneticist (Co-opted member) |
| Rose Woodward | Lay Member |

1. Welcome, Introductions and DOIs

The Chair (BS) welcomed the committee members and NICE attendees to the 6^h committee meeting for the NICE Kidney Cancer guideline.

BS informed attendees that apologies had been received as noted above. BS asked all committee members to verbally declare any new interests.

No new interests were declared but BS reminded the group of the following recorded interest which is relevant to the day's discussion:

| Name | Job title, organisation | Declarations of Interest, date declared | Type of interest | Decision taken |
|---------------|----------------------------------|--|---|---|
| Grant Stewart | Committee member - Topic Adviser | Laird A, Choy KC, Delaney H, Cutress ML, O'Connor KM, Tolley DA, McNeill SA, Stewart GD, Riddick AC. Matched pair analysis of laparoscopic versus open radical nephrectomy for the | Specific, Direct -non-financial professional and personal | Declare and partial exclusion. Participate in discussion but withdraw for drafting recommendations. |

| | | | | |
|---|--|---|--|--|
| | | <p>treatment of T3 renal cell carcinoma. World J Urol. 2015 Jan;33(1):25-32. doi: 10.1007/s00345-014-1280-y. Epub 2014 Mar 20. PMID: 24647880. Declared June 2024</p> | | |
| <p>Grant Stewart (GS) was an author on a paper included in the evidence review being discussed. It was agreed that the member could stay for the discussion of the evidence of review question 4a but would need to step out whilst recommendations were being made.</p> <p>Finally, the minutes from committee 5 were checked and agreed to be an accurate record.</p> | | | | |
| <p>2. RQ 3b (management of localised renal cell carcinoma using non-surgical interventions or active surveillance):</p> <ul style="list-style-type: none"> • Revisit recommendations for 3b • Review merged version of recommendations from reviews 3a and 3b | | | | |
| <p>BS introduced NICE Senior Technical Analyst Olivia Crane (OC), who presented the recommendations previously drafted for review question 3a (partial vs. radial nephrectomy) and 3b for committee review. Revisions were made to the wording based on committee discussion and consensus.</p> <p>BS thanked and moved to the next item on the agenda.</p> | | | | |
| <p>3. RQ 4a (management of locally advanced renal cell carcinoma using nephrectomy or stereotactic ablative radiotherapy):</p> <ul style="list-style-type: none"> • Presentation of clinical evidence • Presentation of health economics evidence | | | | |
| <p>BS introduced Fernando Zanghelini (FZ), Technical Analyst and Hannah Tebbs (HT), Senior Health Economist, who gave an overview of the clinical and economic evidence for review question 4a.</p> | | | | |
| <p>4. Committee Discussion</p> | | | | |
| <p>The committee discussed the evidence presented and had the opportunity to ask any questions.</p> <p>BS thanked FZ and HT for their presentations and moved the discussion on to item 5.</p> | | | | |

5. Equality and health inequality considerations

FZ opened a discussion with the committee on the important matter of health equality issues, highlighting those drafted so far and asking them to consider if there were any missing which should be included based on the evidence presented today.

After a productive discussion BS thanked the committee for their input and moved the discussion on to the drafting of recommendations.

6. Drafting recommendations

GS left the meeting for this agenda item due to conflict of interest.

Taking input from the committee to craft the initial wording, the NICE team were able to draft recommendations for review question 4a that would be taken away for further edits.

BS thanked the committee for their input.

7. Review of protocol 5b (follow-up and monitoring for previously treated renal cell carcinoma):

- **Technical queries**
- **Economic modelling queries**

BS introduced Marie Harrisingh (MH), Topic Lead and Yuanyuan Zhang (YZ), Health Economist.

MH presented several technical questions regarding protocol 5b.

The committee discussed what was presented and provided their input.

YZ gave a presentation on the next steps for economic modelling for review question 5b (monitoring long-term consequences of treatment).

YZ showed the committee three proposed model structures for their consideration and asked their input on options for modelling the impact of different follow up strategies. The committee discussed the options presented and provided their opinion.

BS thanked the committee for their input.

8. Any other protocol queries

MH led the committee discussion to agree confounders for protocol 6bi and 6bii (non-pharmacological interventions before or after SACT) and to consider outcome measures and prognostic scores for protocol 2cii (using classification systems for

prognosis).

BS thanked the team for their work in preparing for the day's discussions and moved the discussion on to any other business.

9. Next steps and AOB

BS summarised the main actions from the day and asked for items of any other business. As there was no further business to discuss, BS brought the meeting to a close.

Date of next meeting: 16/10/2024

Location of next meeting: Virtual